Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 2 1

Status

Recruiting 3Completed 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 4

Conditions

Carcinoma, Non-Small-Cell Lung 29Lung Neoplasms 16Small Cell Lung Carcinoma 10Breast Neoplasms 8Esophageal Neoplasms 5Sarcoma 4Neoplasms 4Melanoma 4Colorectal Neoplasms 4Advanced Lung Cancer 4Stomach Neoplasms 3Ovarian Neoplasms 3Neoplasm Metastasis 3Thoracic Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Mesothelioma 2Colonic Neoplasms 2Cholangiocarcinoma 2Carcinoma, Renal Cell 2Adenocarcinoma of Lung 2Widespread Small Cell Lung Cancer 1Uveal Melanoma 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Uncommon Pathological Types of Lung Cancer 1Thyroid Neoplasms 1Testicular Neoplasms 1Squamous Cell Lung Cancer 1

Interventions

Injections 4toripalimab 3sintilimab 2Carboplatin 2aflutinib 1Surveys and Questionnaires 1Pemetrexed 1Paclitaxel 1Etoposide 1Docetaxel 1Cisplatin 1Chlorogenic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Advanced Lung Cancer × Injections × Thoracic × Clear all
NCT07309276 2026-05-18

A Phase II Clinical Study Evaluating the Combination Therapy of JS212 in Patients With Advanced Lung Cancer

Shanghai Junshi Bioscience Co., Ltd.

Phase 2 Recruiting
864 enrolled
Thoracic

Advanced Lung Cancer

NCT07367529 2026-05-05

A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 1/2 Recruiting
465 enrolled
Thoracic

Advanced Lung Cancer

NCT05664971 2025-12-02

JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer

Shanghai Junshi Bioscience Co., Ltd.

Phase 1/2 Completed
119 enrolled
Thoracic

Advanced Lung Cancer

NCT07229599 2025-11-17

A Study of MHB036C Combined With Anti-tumor Therapies in Patients With Advanced Lung Cancer

Minghui Pharmaceutical (Hangzhou) Ltd

Phase 1/2 Recruiting
300 enrolled
Thoracic

Advanced Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡